Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$71.8M+3.2%$69.54M+5.6%$65.86M+6.7%$61.75M+9.8%$56.23M+11.7%
$20.27M0.0%$20.27M-0.1%$20.28M+2.3%$19.83M+5.8%$18.74M+8.9%
$92.07M+2.5%$89.81M+4.3%$86.15M+5.6%$81.58M+8.8%$74.96M+11.0%
-$92.07M-2.5%-$89.81M-4.3%-$86.15M-5.6%-$81.58M-8.8%-$74.96M-11.4%
$5M-15.9%$5.95M-14.5%$6.96M+7.8%$6.45M+99.0%$3.24M+69.6%
-$87.07M-3.8%-$83.87M-5.9%-$79.19M-5.4%-$75.13M-4.8%-$71.72M-9.7%
-$3.54-3.5%-$3.42
-$89.43M-2.5%-$87.21M-4.3%-$83.6M-5.7%-$79.07M-9.1%-$72.49M-11.8%
-$92.07M-2.5%-$89.81M-4.3%-$86.15M-5.6%-$81.58M-8.8%-$74.96M-11.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Artiva Biotherapeutics, Inc. profitable?
Artiva Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $87.1M over the trailing twelve months, a -79.3% net margin.
What is Artiva Biotherapeutics, Inc.'s earnings per share?
Artiva Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.54.
Where does Artiva Biotherapeutics, Inc.'s income statement data come from?
Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.